Oncopeptides Sees Redemption with Positive Multiple Myeloma Data after ODAC Vote

Oncopeptides released positive data Wednesday from the Phase III LIGHTHOUSE trial of Pepaxto (melflufen) in relapsed refractory multiple myeloma (RRMM) patients.

This comes one month after the FDA’s Oncologic Drugs Advisory Committee (ODAC) meeting in late September that resulted in a 14-2 vote against Pepaxto.